Journal
DRUG DISCOVERY TODAY
Volume 22, Issue 3, Pages 526-533Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2016.09.014
Keywords
-
Categories
Funding
- European Community's Seventh Framework Programme FP7 [260872]
Ask authors/readers for more resources
The flavoenzyme DprEl catalyses a crucial step in arabinan production for cell wall biosynthesis in Mycobacterium tuberculosis and is a highly vulnerable drug target. It was first discovered using benzothiazinones (BTZ): exquisitely potent bactericidal agents that are being developed as drugs to treat tuberculosis. Subsequently, many compounds with diverse scaffolds were found to act as either covalent or noncovalent DprEl inhibitors. Covalent inhibitors, like the BTZ, are all nitroaromatic compounds that serve as suicide substrates after DprEl-mediated nitroreduction. Here, we describe how high resolution structures of DprEl, alone and in complex with various ligands, explain enzyme activity and inhibition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available